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Other names: CDC25A2 
Location: 3p21 
Local order: The gene is located telomeric to CAMP 
(cathelicidin antimicrobial peptide) and centromeric to 
LOC729349 (a pseudogene similar to 60S ribosomal 
protein L17 (L23)). The gene starts at 48,173,672 bp 
from pter and ends at 48,204,805 bp from pter with a 
total size of 31,133 bases. 
DNA/RNA 
Description 
CDC25A is about 31.13 kb located on the short (p) arm 
of chromosome 3, in the centromere-to-telomere 
orientation. The gene has 15 exons and the start codon 
is located at the end of exon 1 and stop codon in the 
beginning of exon 15. 
Transcription 
The CDC25A transcript is 3704 bp in length. So far 
there are two major transcript variant have been  
reported, CDC25A1 and A2. The transcript variant 
CDC25A2, has a deletion of 120 nucleotide (exon 6) 
resulted in a protein having truncation of 40 amino acid 
(between amino acid 143-182). However, both the N-
terminal and C-terminal end of the protein is the same 
in both splice variant. 
Protein 
Description 
The full length CDC25A protein consists of 524 amino 
acids with an estimated molecular weight of 59 kDa. 
The other reported isoform CDC25A2, consists of 484 
amino acids with a molecular weight of 54.4 kDa. Both 
the isoforms have the same N- and C-terminal end, thus 
expected to have similar catalytic activity. The N-
terminal regulatory domain contains several 
phosphorylation sites and show low sequence 
homology between CDC25 family members, whereas 
C-terminal end has conserved Rhodanese homology 
domain containing the active site cysteine. The 
catalytic site contain the CX5R motif (C= cysteine; X= 





Genomic organization of human CDC25A gene on chromosome 3 p-ter. 






Atlas Genet Cytogenet Oncol Haematol. 2008;12(6)  422 
 
Domains of different isoforms of CDC25A (A1 and A2). The splice variant A2 lacks an in-frame exon (exon 6) encoding 40 amino acids 
(amino acid 143-182), however, have the same N- and C-termini compared to isoform A1. The approx. molecular weight of each isoform 
is mentioned in parenthesis. 
Expression 
CDC25A is expressed early during embryonic stages 
and in adults it is expressed in a variety of normal cells 
and tissues. CDC25A is a highly expressed gene in a 
variety of human cancers including breast, esophageal, 
gastric, lung, thyroid, head and neck cancers and also in 
high grade lymphomas. 
Localisation 
CDC25A initially believed to be a nuclear protein. But 
using fluorescence loss in photobleaching (FLIP) the 
more dynamic nuclear-cytosolic shuttling of CDC25A 
localization have been reported. At the very N-terminus 
end between amino acid 38-59, the nuclear export 
sequence (NES) is located, whereas between amino 
acid 272-294, a bipartite nuclear localization signal 
(NLS) proved to be important for its nuclear 
localization. 
Function 
- It is a member of the M-phase inducer (MPI) 
phosphatase family protein, which not only regulates 
mitotic progression by activating mitotic CDKs in a 
dosage-dependent manner, it is also equally important 
for G1 to S-phase transition. 
- During G1 to S transition, it activates CDK2 by 
removing two inhibitory phosphates on residues 
threonine 14 and tyrosine 15. During G2/M transition 
CDC25A similarly regulates the activity of CDK1 
(CDC2). 
- It is an important checkpoint protein in response to 
damage by ionizing radiation (IR), ultraviolet light 
(UV), replication inhibitor and by various DNA 
damaging agents. In response to DNA damage, 
CDC25A undergoes CHK1/CHK2 -mediated 
phosphorylation followed by ubiquitination-dependent 
degradation leading to growth arrest in a p53 -
independent manner. 
- CDC25A is essential for early embryonic 
development as Cdc25A-null mice die in utero by 
embryonic day 7. 
- CDC25A is overexpressed in a variety of human 
cancers including breast, esophageal, gastric, lung, 
thyroid, head and neck cancers and lymphomas. 
CDC25A overexpression at least in breast cancer is 
mainly due to post-translation stabilization as oppose to 
gene amplification or transcriptional upregulation. 
- CDC25A protein level is important for oncogene-
induced transformation and mouse mammary tumor 
virus (MMTV)-neu/ras induced mammary 
tumorigenesis. 
- During early cell cycle progression glycogen synthase 
kinase 3-beta (GSK-3beta) can phosphorylate and 
degrade CDC25A, thus maintain the lower cellular 
levels of CDC25A. Interestingly, the same report 
showed that overproduction of CDC25A in human 
cancers is correlated to the inactivation of GSK-3beta. 
- It is an inhibitor of apoptosis by inhibiting apoptosis 
signal-regulating kinase 1 (ASK1). 
- CDC25A plays an important role in spermatogenesis 
as decreased transcript level of Cdc25A is correlated 
with spermatogenic failure and failed sperm retrieval in 
infertile men. 
Homology 
CDC25A gene is highly conserved among mammals 
(99% homology with Chimpanzee; 90% with dog; 
about 86% with rat and about 85% with mouse). In 
mammals, CDC25A has two orthologs, CDC25B and 
CDC25C. Among them, the N-terminal regulatory 
region show low sequence homology (20-25% 
identity), however, the C-terminal catalytic region is 
quite conserved with about 64% homology with 
CDC25B and about 58% homology to CDC25C. 
Mutations 
Note: Gene mutation or amplification is not commonly 
reported for CDC25A. A naturally occurring point 
mutation (C to A) of mouse Cdc25A gene has been 
reported where Histidine 128 (CAC) has been 
converted to Glutamine (CAA). This change caused an 
increase in CDC25A phosphatase activity and thereby 
affected erythropoiesis in mice only under certain 
genetic background. 
Implicated in 
Note: CDC25A is overexpressed in a variety of human 
cancers including breast, hepatocellular, ovarian, 
colorectal, esophageal, head and neck cancer and also 
in non-Hodgkin lymphoma. 
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Breast cancer 
Note: - In about 47% of early (T1) stage breast cancer 
patients CDC25A is reported to be overexpressed. 
- Although the mechanism of CDC25A upregulation in 
human patients is not yet clear, however, in some 
breast cancer cell lines it was reported that CDC25A 
overexpression is mainly due to increased protein 
stability as oppose to gene amplification or 
transcriptional upregulation. 
- In mice, overexpression of CDC25A alone in 
mammary gland using mouse mammary tumor virus 
(MMTV) promoter, is not sufficient to induce 
mammary tumorigenesis. However, such mammary 
specific overexpression of CDC25A does cooperate 
with HER2/neu-ras signaling to form more aggressive 
tumors with enhanced genomic instability. 
- In contrast, hemizygous loss of Cdc25A in mice 
protected them significantly from MMTV-neu/ras-
induced mammary tumorigenesis, possibly by 
restricting precancerous cell proliferation and also by 
enhancing G2-checkpoint response. Thus the protein 
level of CDC25A is crucial for the initiation and/or 
progression of breast tumorigenesis in mice. 
Prognosis 
Overexpression of CDC25A is correlated with more 
aggressive breast cancer with poor prognosis. 
Cytogenetics 
CDC25A overexpression in MMTV-CDC25A; 
MMTV-neu double transgenic mice caused faster 
tumor growth as compared to MMTV-neu single 
transgenic mice. Importantly, such CDC25A 
overexpressing tumor cells displayed miscoordination 
of S phase and mitosis, and had severe genomic 
instability as evidenced by aneuploidy and deletion of 
fragile chromosomal regions (e.g., telomeric region of 
chromosome 4, which is homologous to human 
chromosome 1p31-36, a hotspot for several human 
cancers including breast cancer). 
Hepatocellular carcinoma 
Note: Different CDC25 inhibitor (such as vitamin K 
analog Cpd 5; phenyl maleimide compound PM-20; 2-
Methoxyestadiol, a physiological metabolite of 
estrogen) are capable of inhibiting the hepatocellular 
carcinoma growth both in vitro and in vivo. 
Prognosis 
CDC25A overexpression is associated with poor 
prognosis of hepatocellular carcinoma. 
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